An algorithmic Matching Score is described that evaluates cancer drugs’/drug combinations’ ability to address a patients’ entire next-generation sequencing/multi-omic-derived molecular profile and underscores the clinical importance of the precision medicine approach that maximizes matching of multiple molecular alterations with cognate drugs.
Abstract
Historically, precision medicine implies matching one biomarker to cognate monotherapies. However, next-generation precision oncology must address cancer complexity. Indeed, advanced tumors have a median of five genomic alterations; with ~700 cancer-causing genes, there are >1 trillion patterns. We describe an algorithmic Matching Score (expert-curated knowledge base within a digital reasoning framework) that evaluates cancer drugs’/drug combinations’ ability to address a patients’ entire next-generation sequencing/multi-omic-derived molecular profile. Using prospective, peer-reviewed published clinical trial and other study results analyzed retrospectively, Matching Scores were produced for 540 advanced/metastatic cancer patients (number of unique pathogenic alterations = 374); the most common cancers were breast (
n
= 98) and colorectal (
n
= 64). Matching Score results was evaluated with Kaplan–Meier, Univariate and Multivariate Cox regression analyses demonstrating that Matching Scores correlated significantly with improved progression-free survival (0% vs. 67–100% matching: 3.0 vs. 9.0 months, hazard ratio (HR): 0.34,
P
< 0.01), overall survival (0% vs. 67–100% matching: 9.0 vs. 18.7 months, HR: 0.54,
P
< 0.01), and clinical benefit rate (stable disease≥6 months/objective response) (0% vs. 67–100% matching: 22.1% vs. 55.9%, odds ratio: 4.59,
P
< 0.01). This study underscores the clinical importance of the precision medicine approach that maximizes matching of multiple molecular alterations with cognate drugs.
Biochemical recurrence (BCR), defined as any detectable prostate-specific antigen level after prostatectomy with confirmatory elevation, is widely used as a surrogate endpoint and typically assessed using clinical and pathological variables. Currently, no standardized benchmark exists for multimodal prognostic modeling...
Robert N. Spaans, C. Chia, Tong-Jie Wang et al.· 0 citations
An interpretable three-stage machine learning framework integrating mRNA, microRNA, DNA methylation, copy number variation, and protein expression data from The Cancer Genome Atlas that couples improved prognostic estimation with biological interpretability supporting multi-omics biomarker discovery in ovarian cancer.
Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecula...
M. Griffiths, Jennifer J. Knox, G. O'Kane et al.· Frontiers in Artificial Inte...· 0 citations
An electronic health record-based prognostic model is developed to identify patients with metastatic breast cancer at high risk of near-term death and can predict risk of death within 30 and 90 days for patients with MBC.
E. Ray, Xin-Yi Zhang, Lisette N. Dunham et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Cancer is the leading cause of disease-related mortality in children. Next-generation sequencing (NGS) has emerged as a critical tool in precision oncology, enabling the identification of somatic genomic alterations that may inform diagnosis, prognosis, and therapy. This study evaluated the clinical utility...
H. Cohen, Iris Kventsel, S. Caspi et al.· Pediatric Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.